Muscular Disorders, Atrophic: Clinical Trials

878 trials for Muscular Disorders, Atrophic, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

429 completed, 127 recruiting, 99 unknown, 75 terminated. 221 Not applicable, 196 Phase 2, 136 Phase 1, 90 Phase 3, 11 Phase 4.

By phase and status

PhaseTrialsStatus
Not applicable221Completed 124, Unknown 31, Recruiting 28, Active not recruiting 13, Not yet recruiting 9, Enrolling by invitation 6, Terminated 5, Withdrawn 5
Phase 2196Completed 93, Terminated 36, Active not recruiting 23, Recruiting 19, Unknown 11, Enrolling by invitation 7, Withdrawn 4, Not yet recruiting 3
Phase 1136Completed 75, Recruiting 15, Terminated 13, Unknown 13, Active not recruiting 12, Withdrawn 5, Enrolling by invitation 2, Not yet recruiting 1
Phase 390Completed 42, Terminated 20, Recruiting 10, Active not recruiting 5, Unknown 5, Withdrawn 5, Enrolling by invitation 3
Phase 411Completed 4, Active not recruiting 2, Recruiting 2, Unknown 2, Terminated 1
Early Phase 19Active not recruiting 3, Recruiting 3, Completed 2, Terminated 1

Follow Muscular Disorders, Atrophic: new trials by email Literature Review of Muscular Disorders, Atrophic trials Research Report on Muscular Disorders, Atrophic

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
iBCI Optimization for Veterans With Paralysis
Mobile neural decoding platform (mobile iBCI) - Spinal Cord Injury, Amyotrophic Lateral Sclerosis
Not applicableNot yet recruitingVA Office of Research and Development22027-04-142026-11-16
Interfacing With NeuroTechnology to Expand Neural Throughput (INTENT)
INTENT Neural Interface System - Tetraplegia/Tetraparesis, Amyotrophic Lateral Sclerosis (ALS)
Not applicableRecruitingJohns Hopkins University52027-01-012026-10-09
A Study of SAT-3247 to Evaluate the Safety, Tolerability, and Efficacy in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)
forazapadin, Placebo Comparator - Facioscapulohumeral Muscular Dystrophy (FSHD)
Phase 2Not yet recruitingSatellos Bioscience, Inc.512026-12-152026-10-13
Multimodal Study About Absence of Dp140 in Becker Muscular Dystrophy: Brain-muscle Imaging, Cognition and Muscle Function
Becker Muscular Dystrophy
Not yet recruitingInstitut de Myologie, France752026-12-152026-11-03
Calcium Channel Blocker in Myotonic Dystrophy Type 1
Amlodipine - Myotonic Dystrophy 1
Phase 1Not yet recruitingUniversity of Rochester202026-12-072026-11-09
Glucagon-Like Peptide-1 Receptor Agonists to Attenuate Metabolic Risk in Individuals With Duchenne Muscular Dystrophy
Semaglutide (Rybelsus®), Placebo - Duchenne Muscular Dystrophy (DMD)
Phase 1 / Phase 2RecruitingVanderbilt University Medical Center302026-12-012026-11-12
Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Participants With Duchenne Muscular Dystrophy Treated in a Post-Marketing Setting
ELEVIDYS, Sirolimus, Glucocorticoids - Duchenne Muscular Dystrophy
Phase 4RecruitingSarepta Therapeutics, Inc.202026-11-302026-11-12
A Phase 2 Trial to Investigate the Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tegacorat in Male Participants 4 to <7 Years of Age With Duchenne Muscular Dystrophy
Tegacorat - Duchenne Muscular Dystrophy (DMD)
Phase 2Not yet recruitingGrünenthal GmbH362026-11-092026-11-03
Urotherapy Education for Families of Children With Duchenne Muscular Dystrophy
Urotherapy Education - Duchenne Muscular Dystrophy (DMD), Lower Urinary Tract Symptoms (LUTS)
Not applicableNot yet recruitingLokman Hekim University502026-11-012026-09-15
Metabolomic Biomarkers of Myotonic Dystrophy
Myotonic Dystrophy Type 1
RecruitingMassachusetts General Hospital642026-10-262026-11-03
Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) Extension
DM1, Myotonic Dystrophy
RecruitingVirginia Commonwealth University10002026-10-152026-10-16
Safety and Efficacy of KER-065 in Participants With Duchenne Muscular Dystrophy
KER-065 - Duchenne Muscular Dystrophy
Phase 2RecruitingKeros Therapeutics, Inc.362026-09-252026-11-13
Personalized Disease Modeling for Rare Genetic Myopathies
Congenital Myopathies, Muscular Dystrophy
Enrolling by invitationAkron Children's Hospital32026-09-222026-11-03
Intermittent vs Alternate Daily Regimen of Prednisolone in Ambulatory Boys With Duchenne Muscular Dystrophy
Alternate-day prednisolone, Intermittent prednisolone - Duchenne Muscular Dystrophy
Not applicableNot yet recruitingMuhammad Aamir Latif402026-09-152026-08-26
A Trial to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of SFL-0821 in Adults With FSHD
SFL-0821 for injection, Placebo - Facioscapulohumeral Muscular Dystrophy (FSHD)
Phase 1 / Phase 2RecruitingSoufflé Therapeutics, Inc.902026-09-012026-10-30
A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping
AOC 1044, Placebo - Muscular Dystrophies, Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy)
Phase 3RecruitingAvidity Biosciences, Inc.702026-09-012026-11-10
Self-Efficacy Enhancement Among Online Support Group of Primary Caregivers of Children With Neuro Muscular Dystrophy
Multicomponent Intervention - Duchenne Muscular Dystrophy (DMD), Spinal Muscular Atrophy (SMA)
Not applicableActive not recruitingAga Khan University342026-08-152026-10-09
An Ambispective Natural History Study in Myotonic Dystrophy Patients Linking Retrospective Data Captured From the DM-Scope Registry With a Prospective 24-month Follow-up Period
Myotonic Dystrophy 1, Myotonic Dystrophy 2
Not yet recruitingLupin Ltd.1002026-08-032026-07-28
Long-Term Extension Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon Skipping to Evaluate the Safety and Efficacy of Endosomal Escape Vehicle Phosphorodiamidate Morpholino Oligomer Platform Products (ELEVATE-LTE)
ENTR-601-44, ENTR-601-45 - Duchenne Muscular Dystrophy (DMD)
Phase 2Not yet recruitingEntrada Therapeutics, Inc.802026-08-012026-07-02
Effect of Knee Position on Muscle Loss During Leg Immobilization
Knee immobilization brace (0°) for 5 days, Knee immobilization brace (60°) for 5 days - Muscle Atrophy, Disuse Atrophy
Not applicableRecruitingWageningen University302026-08-012026-11-13

Showing 20 of 878. Sign in to see all of them.

Narrower conditions

Muscular Dystrophy, Duchenne (480)  ·  Muscular Dystrophies (224)  ·  Myotonic Dystrophy (126)  ·  Muscular Dystrophy, Facioscapulohumeral (75)  ·  Neuromuscular Diseases (74)  ·  Muscular Dystrophies, Limb-Girdle (46)  ·  Muscular Diseases (41)  ·  Muscular Atrophy, Spinal (32)  ·  Amyotrophic Lateral Sclerosis (30)  ·  Postpoliomyelitis Syndrome (28)  ·  Spinal Cord Injuries (27)  ·  Musculoskeletal Diseases (26)  ·  Motor Activity (25)  ·  Genetic Diseases, Inborn (22)

Broader conditions

Nervous System Diseases (857)  ·  Musculoskeletal Diseases (852)  ·  Muscular Diseases (837)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (816)  ·  Neuromuscular Diseases (804)  ·  Genetic Diseases, Inborn (795)  ·  Muscular Dystrophies (591)  ·  Genetic Diseases, X-Linked (480)  ·  Neurodegenerative Diseases (206)  ·  Heredodegenerative Disorders, Nervous System (148)  ·  Myotonic Disorders (126)  ·  Central Nervous System Diseases (110)  ·  Pathological Conditions, Signs and Symptoms (110)  ·  Spinal Cord Diseases (87)

Interventions

ataluren (13)  ·  eteplirsen (12)  ·  Exercise (11)  ·  Prednisone (11)  ·  VBP15 compound (9)  ·  deflazacort (8)  ·  Tadalafil (7)  ·  Sodium Chloride (6)  ·  givinostat (6)  ·  givinostat hydrochloride (6)  ·  idebenone (6)  ·  Adrenal Cortex Hormones (5)  ·  Physical Therapy Modalities (5)  ·  casimersen (5)  ·  golodirsen (5)

Sponsors

Sarepta Therapeutics, Inc. (38)  ·  Hacettepe University (22)  ·  PTC Therapeutics (19)  ·  Cooperative International Neuromuscular Research Group (16)  ·  Assistance Publique - Hôpitaux de Paris (14)  ·  Copenhagen University Hospital, Rigshospitalet (14)  ·  Avidity Biosciences, Inc. (11)  ·  BioMarin Pharmaceutical (11)  ·  University of Rochester (11)  ·  National Institute of Neurological Disorders and Stroke (NINDS) (10)  ·  Nationwide Children's Hospital (10)  ·  University of Florida (10)  ·  Virginia Commonwealth University (10)  ·  NS Pharma, Inc. (9)  ·  Santhera Pharmaceuticals (9)

Countries

United States (394)  ·  France (130)  ·  United Kingdom (126)  ·  Canada (123)  ·  Italy (122)  ·  Spain (85)  ·  Turkey (Türkiye) (81)  ·  Germany (70)  ·  Belgium (68)  ·  Netherlands (68)  ·  Australia (56)  ·  Denmark (45)  ·  Israel (37)  ·  Sweden (33)  ·  Japan (32)

Top investigators

Nicholas Johnson, MD (6)  ·  Craig McDonald, MD (5)  ·  Kevin Flanigan, MD (5)  ·  Paula R Clemens, MD (5)  ·  Ronald G Victor, MD (5)  ·  Diana M Escolar, MD (4)  ·  Dirk Fischer, MD (4)  ·  Francesco Bibbiani, MD (4)  ·  Mark Awadalla (4)  ·  Carlos BM Monteiro, Ph.D. (3)

Results publications

PMID 32956407, PMID 37539981, PMID 41671094, PMID 42613652, PMID 24919692, PMID 26573217, PMID 27358494, PMID 32434278, PMID 32522498, PMID 32851872, PMID 34693725, PMID 34779542, PMID 35794169, PMID 38190001, PMID 38521535, PMID 38753764, PMID 40152935, PMID 41058127, PMID 41774261, PMID 42139656, PMID 42202243, PMID 10025486, PMID 10747199, PMID 10826123, PMID 10836341, PMID 1108172, PMID 11751186, PMID 11972163, PMID 12030525, PMID 12122118, PMID 12210323, PMID 12351998, PMID 12409823, PMID 1281472, PMID 13997180, PMID 14510658, PMID 14760317, PMID 15293280, PMID 15302625, PMID 15781190, PMID 1580445, PMID 15984021, PMID 16055882, PMID 16267188, PMID 16602102, PMID 16713921, PMID 16763895, PMID 16763896, PMID 16849828, PMID 16900450

NIH funding

2023 (12), 2015 (8), 2019 (7), 2025 (6), 2016 (5), 2017 (4), 2014 (3), U54NS048843 (3), 2008 (2), 2009 (2), R44NS095423 (2), U34AR068616 (2), 1DP2DC021055 (1), 2018 (1), 2026A (1)